AG
AURA icon

Ascent Group’s Aura Biosciences AURA Stock Holding History

Ascent Group’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,964
Closed -$87.4K – 741
2025
Q2 		$87.4K Sell
13,964
-7,224
-34% -$42.3K ﹤0.01% 716
2025
Q1 		$124K Buy
+21,188
New +$160K 0.01% 683

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ascent Group's AURA Position: Q3 2025 in Review

Ascent Group sold out of Aura Biosciences (AURA) in Q3 2025, closing a stake of 13,964 shares — an estimated $87.4K sold.

Ascent Group first reported a position in AURA in Q1 2025 and held it in 2 quarters. The position peaked at $124K in Q1 2025. 106 funds tracked by Wall St. Rank hold AURA as of Q3 2025.

  • Ascent Group reported no remaining Aura Biosciences position as of Q3 2025 after selling out during the quarter.
  • Ascent Group sold 13,964 Aura Biosciences shares in Q3 2025, an estimated $87.4K.
  • Ascent Group first reported a position in Aura Biosciences in Q1 2025 and held it in 2 quarters.
  • Ascent Group's Aura Biosciences position peaked at $124K in Q1 2025.
  • 106 funds tracked by Wall St. Rank held Aura Biosciences as of Q3 2025.

Based on Ascent Group's 13F filing for Q3 2025, filed 20 Oct 2025.